title: The successful treatment of symptomatic, refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt.
abstract: Hepatic hydrothorax is a rare complication of portal hypertension. Conservative therapy may be successful but refractory hepatic hydrothorax is not uncommon. Management of refractory hydrothorax is usually ineffective and can result in a worsened clinical status. Transjugular intrahepatic portosystemic shunts (TIPS) lower portal pressure and have been used in the treatment of refractory ascites. The aim of this study was to determine the efficacy of TIPS in the treatment of symptomatic refractory hepatic hydrothorax. A TIPS was placed in 24 consecutive cirrhotic patients with symptomatic refractory hepatic hydrothorax. Five patients (20.8%) were Child's/Pugh class B and 19 (79.2%) were class C. All had undergone multiple thoracenteses and were hypoalbuminemic. Mean follow-up was 7.2 months (range, 0.25-49 months). Fourteen (58.3%) of 24 patients had complete relief of symptoms after shunt placement and did not require further thoracentesis. Five (20.8%) additional patients required fewer thoracenteses. Five (20.8%) patients developed worsening liver function and died within 45 days. In eight (66.7%) of 12 patients with > or = 60 days of follow-up, the serum albumin increased by a mean of 1.2 g/dL (range, 0.1-2.2 g/dL). The Child's-Pugh score improved in 7 (58.3%) of these 12 patients and two patients improved from class C to class A. These two patients no longer require liver transplantation. This study shows that TIPS can be effective in the management of symptomatic, refractory hepatic hydrothorax. Clinical and laboratory improvement may be seen and liver transplantation may become unnecessary.
authors.affiliation: Department of Medicine, Deaconess Hospital, Harvard Medical School, Boston, MA 02215, USA.
authors.forename: F D
authors.initials: FD
authors.lastname: Gordon
authors.forename: H T
authors.initials: HT
authors.lastname: Anastopoulos
authors.forename: W
authors.initials: W
authors.lastname: Crenshaw
authors.forename: B
authors.initials: B
authors.lastname: Gilchrist
authors.forename: N
authors.initials: N
authors.lastname: McEniff
authors.forename: K R
authors.initials: KR
authors.lastname: Falchuk
authors.forename: J
authors.initials: J
authors.lastname: LoCicero
authors.forename: W D
authors.initials: WD
authors.lastname: Lewis
authors.forename: R L
authors.initials: RL
authors.lastname: Jenkins
authors.forename: C
authors.initials: C
authors.lastname: Trey
mesh_terms: D005260:Female; D006801:Humans; D006876:Hydrothorax / Q000209:etiology* / Q000503:physiopathology / Q000601:surgery*; D008107:Liver Diseases / Q000150:complications*; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D019168:Portasystemic Shunt, Transjugular Intrahepatic / Q000009:adverse effects*; D012120:Respiration Disorders / Q000209:etiology; D012709:Serum Albumin / Q000032:analysis; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D012709:Serum Albumin